Ouro Fino Saúde Animal Participações Past Earnings Performance
Past criteria checks 2/6
Ouro Fino Saúde Animal Participações's earnings have been declining at an average annual rate of -11.1%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 9.7% per year. Ouro Fino Saúde Animal Participações's return on equity is 12.5%, and it has net margins of 9.5%.
Key information
-11.1%
Earnings growth rate
-11.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 9.7% |
| Return on equity | 12.5% |
| Net Margin | 9.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We Think Ouro Fino Saúde Animal Participações' (BVMF:OFSA3) Healthy Earnings Might Be Conservative
Aug 15
One Ouro Fino Saúde Animal Participações S.A. (BVMF:OFSA3) Analyst Just Cut Their EPS Forecasts
May 19Is Ouro Fino Saúde Animal Participações (BVMF:OFSA3) A Risky Investment?
Dec 20These 4 Measures Indicate That Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Is Using Debt Reasonably Well
Jul 28We Think Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Can Stay On Top Of Its Debt
Feb 01Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Has A Pretty Healthy Balance Sheet
May 27Is Now The Time To Put Ouro Fino Saúde Animal Participações (BVMF:OFSA3) On Your Watchlist?
Mar 01Does Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Have A Healthy Balance Sheet?
Feb 08Ouro Fino Saúde Animal Participações S.A.'s (BVMF:OFSA3) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 21Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Is Growing Earnings But Are They A Good Guide?
Jan 03
Introducing Ouro Fino Saúde Animal Participações (BVMF:OFSA3), A Stock That Climbed 42% In The Last Three Years
Dec 15Should You Be Adding Ouro Fino Saúde Animal Participações (BVMF:OFSA3) To Your Watchlist Today?
Nov 27What You Can Learn From Ouro Fino Saúde Animal Participações S.A.'s (BVMF:OFSA3) P/E
Aug 09We Think Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Is Taking Some Risk With Its Debt
Jul 13Revenue & Expenses Breakdown
How Ouro Fino Saúde Animal Participações makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 959 | 91 | 269 | 60 |
| 30 Jun 24 | 940 | 54 | 268 | 52 |
| 31 Mar 24 | 954 | -34 | 269 | 55 |
| 31 Dec 23 | 943 | -50 | 274 | 60 |
| 30 Sep 23 | 985 | -23 | 327 | 20 |
| 30 Jun 23 | 1,002 | 17 | 288 | 68 |
| 31 Mar 23 | 1,006 | 111 | 288 | 69 |
| 31 Dec 22 | 1,041 | 131 | 284 | 69 |
| 30 Sep 22 | 989 | 122 | 272 | 67 |
| 30 Jun 22 | 943 | 112 | 264 | 65 |
| 31 Mar 22 | 939 | 120 | 252 | 63 |
| 31 Dec 21 | 905 | 114 | 244 | 59 |
| 30 Sep 21 | 855 | 108 | 240 | 52 |
| 30 Jun 21 | 845 | 119 | 233 | 47 |
| 31 Mar 21 | 787 | 101 | 225 | 43 |
| 31 Dec 20 | 730 | 90 | 217 | 40 |
| 30 Sep 20 | 706 | 83 | 188 | 56 |
| 30 Jun 20 | 635 | 50 | 190 | 46 |
| 31 Mar 20 | 640 | 50 | 204 | 36 |
| 31 Dec 19 | 620 | 46 | 208 | 28 |
| 30 Sep 19 | 598 | 40 | 235 | 0 |
| 30 Jun 19 | 604 | 50 | 231 | 0 |
| 31 Mar 19 | 588 | 60 | 221 | 0 |
| 31 Dec 18 | 589 | 69 | 217 | 0 |
| 30 Sep 18 | 576 | 72 | 205 | 0 |
| 30 Jun 18 | 546 | 60 | 197 | 0 |
| 31 Mar 18 | 522 | 49 | 195 | 0 |
| 31 Dec 17 | 505 | 38 | 196 | 0 |
| 30 Sep 17 | 442 | 3 | 196 | 0 |
| 30 Jun 17 | 437 | 0 | 202 | 0 |
| 31 Mar 17 | 434 | -9 | 210 | 0 |
| 31 Dec 16 | 457 | -5 | 215 | 0 |
| 30 Sep 16 | 523 | 31 | 217 | 0 |
| 30 Jun 16 | 547 | 44 | 218 | 0 |
| 31 Mar 16 | 545 | 58 | 210 | 0 |
| 31 Dec 15 | 534 | 69 | 202 | 0 |
| 30 Sep 15 | 580 | 61 | 245 | 0 |
| 30 Jun 15 | 459 | 50 | 197 | 0 |
| 31 Mar 15 | 414 | 46 | 174 | 0 |
| 31 Dec 14 | 402 | 43 | 172 | 0 |
| 31 Dec 13 | 384 | 54 | 168 | 0 |
Quality Earnings: OFSA3 has high quality earnings.
Growing Profit Margin: OFSA3 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OFSA3's earnings have declined by 11.1% per year over the past 5 years.
Accelerating Growth: OFSA3 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: OFSA3 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.5%).
Return on Equity
High ROE: OFSA3's Return on Equity (12.5%) is considered low.